One-year (or 2-year) all-cause mortality in women versus men after TAVI
| Study | Publish year | Research type | Sex | Number of patients | Length of Follow-up | 1-year or 2-year all-cause mortality | Adjusted HR (95% CI) (reference=male) | P value |
| Vancouver and Quebec City, Canada48 | 2012 | Retrospective, observational | F | 329 | 302 (IQR 44 - 712) days | 2 year: 27.9% | 0.55 (0.37 to 0.81) | =0.003 |
| M | 312 | 2 year: 38.3% | ||||||
| FRANCE 2 Registry41 | 2015 | Prospective, observational | F | 1967 | 1 year | 1 year:19.3% | 0.71 (0.57 to 0.88) | <0.002 |
| M | 2005 | 1 year:23.7% | ||||||
| TVT registry23 | 2016 | Retrospective, observational | F | 11 808 | 1 year | 1 year: 21.3% | 0.73 (0.63 to 0.85) | <0.001 |
| M | 11 844 | 1 year: 24.5% | ||||||
| Kodali et al 42 | 2016 | Secondary analysis of the randomised trial | F | 1220 | 1 year | 1 year: 19.0% | 0.72 (0.61 to 0.86) | <0.001 |
| M | 1339 | 1 year: 25.9% | ||||||
| Ontario, Canada49 | 2017 | Retrospective, observational | F | 453 | 3.5 years |
1 year: 18.2%
At last follow-up: 41.2% |
0.97 (0.67 to 1.39) for 1 year;
0.91 (0.72 to 1.15) for last follow-up |
0.85 for 1 year death;
0.44 for death at last follow-up |
| M | 546 |
1 year: 19.2%;
At last follow-up: 44.0% | ||||||
| Brazilian registry50 | 2017 | Prospective, observational | F | 418 | 497±478 days | At last follow-up: 29.7% | 0.912 (0.71 to 1.19) | =0.52 |
| M | 401 | At last follow-up: 25.9% | ||||||
| Szerlip et al 47 | 2018 | Secondary analysis of randomised trial | F | 657 | 1 year | 1 year: 9.4% | 0.91 (0.66 to 1.25) | =0.56 |
| M | 1004 | 1 year: 10.4% | ||||||
| Sannino et al 39 | 2018 | Retrospective, observational | F | 423 | 1 year | 1 year: 7% | 0.42 (0.23 to 0.76) | =0.004 |
| M | 487 | 1 year: 12.7% | ||||||
| Saad et al 43 | 2018 | Meta-analysis | F | 23 303 | 3.28±1.04 years | 1 year: 16% | 0.88 (0.82 to 0.94) | <0.001 |
| M | 23 885 | 1 year: 19% |
IQR, interquartile range; TAVI, transcatheter aortic valve implantation.